Product Information
ABILIFY ASIMTUFII 720 MG/2.4 ML is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $1785.2269 per ML under NDC 59148010280. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Apr 27, 2023.
The High Outlier badge above means this manufacturer's average price in the Aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
720 mg/2.4mL
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148010280
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
ARIPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA217006FDA Approved
4/27/2023
On Market Since
4/27/2023
Pharmacological Classes
Price Statistics
The NADAC for ABILIFY ASIMTUFII 720 MG/2.4 ML has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 6.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1785.2269 per ML |
|---|---|
| All-time high | $1785.6575 (Sep 16, 2026) |
| All-time low | $1681.2338 (May 22, 2024) |
| 52-week high | $1785.6575 |
| 52-week low | $1723.9799 |
| Median price | $1735.8802 |
| Average price | $1732.0045 |
| Largest weekly change | +3.0% (Jan 8, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Aripiprazole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Otsuka America Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aripiprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ABILIFY ASIMTUFII 720 MG/2.4 ML?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY ASIMTUFII 720 MG/2.4 ML, manufactured by Otsuka America Pharmaceutical Inc., is $1785.2269 per ML (NDC 59148010280), effective Sep 30, 2026.
How has the price of ABILIFY ASIMTUFII 720 MG/2.4 ML changed over time?
Over the history we have for it, the NADAC for ABILIFY ASIMTUFII 720 MG/2.4 ML has risen 6.0%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ABILIFY ASIMTUFII 720 MG/2.4 ML?
Since Apr 17, 2024, the NADAC for ABILIFY ASIMTUFII 720 MG/2.4 ML has ranged from a low of $1681.2338 (May 22, 2024) to a high of $1785.6575 (Sep 16, 2026), with a median of $1735.8802 per ML.
Are there cheaper alternatives to ABILIFY ASIMTUFII 720 MG/2.4 ML?
No other NADAC-published product currently shares the active ingredient and strength of ABILIFY ASIMTUFII 720 MG/2.4 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ABILIFY ASIMTUFII 720 MG/2.4 ML?
ABILIFY ASIMTUFII 720 MG/2.4 ML (NDC 59148010280) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.